Skip to main content

Table 1 Patient characteristics

From: Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial

Median age 52.5 (23–74) Treatment  
Menoposal status   Neoadjuvant chemotherapy 11 (22.5%)
premenopausal 21 (42.9%) Adjuvant chemotherapy 32 (65.3%)
postmenopausal 28 (57.1%) Recurrence chemotherapy 6 (12.2%)
ECOG performance   Combined therapy  
0 48 (98.0%) Trastuzumab 27 (55.1%)
1 1 (2.0%) Bevasizumab 6 (12.2%)
Dominant hand   No combined therapy 16 (32.7%)
R 48 (98.0%) History of chemotherapy  
L 1 (2.0%) No 20 (40.8%)
Glove size(control side)   Yes 29 (59.2%)
5.5 17 (73.9%) Previous chemotehrapy regimen  
6.0 23 (46.9%) Anthracyclin based 28 (57.1%)
6.5 9 (18.4%) Docetaxel 1 (2.0%)
Location of primary tumor   Smoking status  
R 18 (36.7%) Never smoker 36 (73.5%)
L 30 (61.2%) Current smoker 3 (6.1%)
Bilateral 1 (2.0%) Former smoker 6 (12.2%)
Axillary dissection   Unknown 4 (8.2%)
No 26 (55.3%) Diabetes  
Yes 21 (44.7%) No 45 (91.8%)
Subtype of the primary tumor   Yes 4 (8.2%)
ER+/HER2- 11 (22.9%)   
ER+/HER2+ 18 (37.5%)   
ER−/HER2+ 8 (16.7%)   
ER−/HER2- 11 (22.9%)